A Randomized, Double-blinded, Placebo-controlled Study of Rituximab in Patients with Psychosis And/or Obsessive Compulsive Disorder, with an Indication of Immune System Involvement

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Rituximab (Primary) ; Cetirizine; Methylprednisolone sodium succinate; Paracetamol
Indications Obsessive-compulsive disorders; Psychotic disorders
Focus Therapeutic Use
Acronyms Ra-P-OCD

19 Nov 2024 Planned End Date changed from 1 May 2026 to 1 Dec 2028.
19 Nov 2024 Planned primary completion date changed from 1 Apr 2026 to 1 Apr 2028.
16 May 2022 Planned End Date changed from 1 May 2025 to 1 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com